OTCMKTS:FSNUY Fresenius SE & Co. (FSNUY) Stock Price, News & Analysis $14.28 -0.40 (-2.72%) As of 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendEarningsNews and TrendsSEC FilingsShort Interest About Fresenius SE & Co. Stock (OTCMKTS:FSNUY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Fresenius SE & Co. alerts:Sign Up Key Stats Today's Range$14.22▼$14.8150-Day Range$11.71▼$14.9952-Week Range$10.33▼$15.94Volume131,380 shsAverage Volume90,965 shsMarket Capitalization$32.17 billionP/E Ratio14.53Dividend Yield1.40%Price TargetN/AConsensus RatingBuy Company Overview Fresenius SE & Co. KGaA is a German healthcare group headquartered in Bad Homburg. Its businesses include Fresenius Kabi, which supplies medicines, clinical nutrition, infusion therapies and medical technologies, and Fresenius Helios, which operates hospitals in Germany and Spain. Fresenius Kabi serves healthcare providers around the world, while Helios focuses on hospital and healthcare services in Europe. The group traces its origins to a pharmacy in Frankfurt acquired by pharmacist Eduard Fresenius in 1912. Michael Sen has served as Fresenius’s chief executive officer since 2022. Through its businesses, the company provides products and services across areas including hospital care, pharmaceuticals and medical technology.AI Generated. May Contain Errors. Read More Fresenius SE & Co. Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreFSNUY MarketRank™: 3.461380161885 of 5 starsFresenius SE & Co. scored higher than 69% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingBuy Consensus RatingFresenius SE & Co. has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFresenius SE & Co. has only been the subject of 1 research reports in the past 90 days.Read more about Fresenius SE & Co.'s stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth4.67% Earnings GrowthEarnings for Fresenius SE & Co. are expected to grow by 4.67% in the coming year, from $1.07 to $1.12 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fresenius SE & Co. is 14.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.28.Price to Earnings Ratio vs. SectorThe P/E ratio of Fresenius SE & Co. is 14.53, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 31.95.Price to Book Value per Share RatioFresenius SE & Co. has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Fresenius SE & Co. has been sold short.Short Interest Ratio / Days to CoverFresenius SE & Co. has a short interest ratio ("days to cover") of 0.32, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Fresenius SE & Co. has recently decreased by 85.35%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldFresenius SE & Co. pays a meaningful dividend of 1.38%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthFresenius SE & Co. does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Fresenius SE & Co. is 25.00%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Fresenius SE & Co. will have a dividend payout ratio of 17.86% next year. This indicates that Fresenius SE & Co. will be able to sustain or increase its dividend.Read more about Fresenius SE & Co.'s dividend. News and Social Media2.9 / 5News SentimentN/A News SentimentFresenius SE & Co. has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Fresenius SE & Co. this week, compared to 1 article on an average week.Search Interest1 people have searched for FSNUY on MarketBeat in the last 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Fresenius SE & Co. insiders have not sold or bought any company stock.Percentage Held by InstitutionsFresenius SE & Co. has minimal institutional ownership at this time.Read more about Fresenius SE & Co.'s insider trading history. Receive FSNUY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fresenius SE & Co. and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FSNUY Stock News HeadlinesFresenius Kabi Launches Denosumab Biosimilars in Canada, with the First and Only Ready-to-Use Pre-Filled Syringe Biosimilar for OncologyNovember 16 at 9:28 AM | markets.ft.comFresenius plans to sell around 13.4 million FMC sharesNovember 11, 2026 | marketscreener.comMWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 19 at 1:00 AM | Base Camp Trading (Ad)Fresenius SE & Co. KGaA (FSNUY) Q3 2026 Earnings Call TranscriptNovember 4, 2026 | seekingalpha.comFresenius expands biosimilar business through partnership with China's WuXiNovember 3, 2026 | marketscreener.comMFresenius, WuXi Enter Development Agreement To Expand Biosimilars PipelineNovember 3, 2026 | rttnews.comJefferies leaves Fresenius SE at 'Buy', target €55November 3, 2026 | marketscreener.comMFresenius SE & Co. KGaA : JP Morgan reaffirms its Buy ratingOctober 26, 2026 | marketscreener.comMSee More Headlines FSNUY Stock Analysis - Frequently Asked Questions How have FSNUY shares performed this year? Fresenius SE & Co.'s stock was trading at $14.33 at the start of the year. Since then, FSNUY stock has decreased by 0.3% and is now trading at $14.28. How were Fresenius SE & Co.'s earnings last quarter? Fresenius SE & Co. (OTCMKTS:FSNUY) announced its earnings results on Wednesday, November, 4th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.22 by $0.03. The business earned $6.52 billion during the quarter, compared to analysts' expectations of $6.51 billion. Fresenius SE & Co. had a net margin of 6.58% and a trailing twelve-month return on equity of 10.24%. How do I buy shares of Fresenius SE & Co.? Shares of FSNUY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Fresenius SE & Co. own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fresenius SE & Co. investors own include Alibaba Group (BABA), Fresenius Medical Care AG & Co. KGaA (FMS), International Business Machines (IBM), Toll Brothers (TOL), Uber Technologies (UBER), Allianz (ALIZY) and Basf (BAS). Company Calendar Last Earnings11/04/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolOTCMKTS:FSNUY CIK904868 Webwww.fresenius.com Phone(496) 172-6080FaxN/AEmployees178,394Year Founded1912Profitability EPS (Trailing Twelve Months)$0.80 Trailing P/E Ratio14.53 Forward P/E Ratio12.75 P/E GrowthN/ANet Income$1.43 billion Net Margins6.58% Pretax Margin9.53% Return on Equity10.24% Return on Assets4.94% Debt Debt-to-Equity Ratio0.41 Current Ratio1.28 Quick Ratio0.97 Sales & Book Value Annual Sales$25.87 billion Price / Sales1.24 Cash Flow$1.52 per share Price / Cash Flow9.39 Book Value$9.93 per share Price / Book1.44Miscellaneous Outstanding Shares2,252,950,000Free FloatN/AMarket Cap$32.17 billion OptionableNot Optionable Beta0.63 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (OTCMKTS:FSNUY) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fresenius SE & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fresenius SE & Co. With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.